drugset / Trial / NCT02055300
Safety, Tolerability and Pharmacokinetics Study of LY03005
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating single oral doses of LY03005 in healthy subjects and to characterize the pharmacokinetics (PK) of escalating single oral doses of LY03005.
Timeline
- Start
- 2014-02
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Desvenlafaxine | Other / unclassified | 50 mg | — |
| Subject | Toludesvenlafaxine | Small molecule | 20 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 40 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 80 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 120 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 160 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 200 mg | Oral |